Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS RATING: 5.23, Impact Factor: RJIF 5.98 | Free Publication Certificate
updates
NAAS Rating: 5.23 new
Vol. 7, Issue 12 (2018)

Formulation and in-vitro evaluation of orodispersible tablets containing naproxen sodium & rizatriptan benzoate

Author(s):
Firdous Unnisa, Syed Abdul Azeez Basha and Shireen Begum
Abstract:
Migraine is a condition characterised by attacks of moderate to severe, throbbing headache requires faster regimens of treatment in preventing of cluster headache for prolonged periods. Orodispersible Tablets (ODT) are most accepted and have gained importance who have difficulty in swallowing & for faster therapeutic benefit. In the present study, orodispersible tablets containing Naproxen sodium as NSAID and Rizatriptan benzoate a potent selective 5-HT1B/1D receptor were prepared by direct compression method employing Superdisintegrants Sodium Starch Glycolate, Croscarmellose sodium and Crospovidone and were evaluated. Naproxen of being BCS (class -II) its Solubility studies were enhanced by compaction technique. All the formulations showed good flow properties such as Angle of repose, Bulk density, Tapped density, Carr’s index & Hausner’s ratio. The orodispersible tablets were evaluated for weight variations, Hardness, Friability, disintegration time, Wetting time and Dissolution rate and were within the permissible limits. FT-IR & DSC Studies established no physicochemical interaction. The Optimized formulation (F9) containing 250mg of Naproxen, 10mg of Rizatriptan with the superdisintegrant crospovidone of 21mg found to have a drug release (99.96%) at 30mins with disintegration time 1min 45sec following first order kinetics. Stability studies indicated no significant changes in physical appearance, disintegration time and % drug release.
Pages: 261-269  |  283 Views  15 Downloads
How to cite this article:
Firdous Unnisa, Syed Abdul Azeez Basha, Shireen Begum. Formulation and <em>in-vitro</em> evaluation of orodispersible tablets containing naproxen sodium &amp; rizatriptan benzoate. Pharma Innovation 2018;7(12):261-269.
The Pharma Innovation Journal